A PI3K Inhibitor with Low Cardiotoxicity and Its Synergistic Inhibitory Effect with Gilteritinib in Acute Myelogenous Leukemia (AML) Cells.

Tianze Wu, Yi Chen, Yimin Gong, Mingzhu Lu, Chengbin Yang, Yannan Yang, Yun Ling, Yaming Zhou

Abstract read

In one paragraph

Article in Molecules (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

SGLT2 Inhibitor Dapagliflozin Attenuates Cardiomyocyte Injury and Inflammation Induced by PI3Kα-Selective Inhibitor Alpelisib and Fulvestrant Under Hyperglycemia.International journal of molecular sciences · 2026
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Tianze WuDepartment of Chemistry, Fudan University, Shanghai 200433, China.

Yi ChenDepartment of Chemistry, Fudan University, Shanghai 200433, China.

Yimin GongDepartment of Chemistry, Fudan University, Shanghai 200433, China.

Mingzhu LuDepartment of Chemistry, Fudan University, Shanghai 200433, China.

Chengbin YangDepartment of Chemistry, Fudan University, Shanghai 200433, China.

Yannan YangSouth Australian immunoGENomics Cancer Institute, The University of Adelaide, Adelaide, SA 5005, Australia.

Yun LingDepartment of Chemistry, Fudan University, Shanghai 200433, China.ORCID 0000-0002-6956-4504

Yaming ZhouDepartment of Chemistry, Fudan University, Shanghai 200433, China.ORCID 0000-0003-2720-9536

Funding

International Science & Technology Innovation Collaboration Project of Shanghai 22520713700National Natural Science Foundation of China 22275037the Commission for Science and Technology of Shanghai 20ZR1404800

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Aniline CompoundsAntineoplastic AgentsCardiotoxicityLeukemia, Myeloid, AcutePhosphoinositide-3 Kinase InhibitorsProtein Kinase InhibitorsPyrazinesSulfonamidesAnimalsApoptosisCell Line, TumorDrug Synergismfms-Like Tyrosine Kinase 3HL-60 CellsHumansMiceAniline CompoundsAntineoplastic Agentsfms-Like Tyrosine Kinase 3gilteritinibPhosphoinositide-3 Kinase InhibitorsProtein Kinase InhibitorsPyrazinesSulfonamides7-azaindazoleacute myelogenous leukemiacardiotoxicitycombination therapyoxidative stressPI3K inhibitor

Identifiers

PMID40509234

DOI10.3390/molecules30112347

PMCPMC12156206

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.